Literature DB >> 24598252

Changes in hepatitis C virus genotype distribution in Japan.

H Toyoda1, T Kumada1, K Takaguchi2, N Shimada3, J Tanaka4.   

Abstract

Genotypes are associated with the natural course of hepatitis C virus (HCV) infection and response to antiviral therapy for HCV. HCV genotype 1b has been the dominant genotype in Japan, where the prevention of HCV transmission through blood transfusion or nosocomial infection has been established since 1990. The distribution of HCV genotype was investigated based on patient's birth year in 5515 HCV-infected Japanese individuals at three institutions from different areas of Japan. At all three institutions, the proportion of HCV genotype 1b decreased and was <50% in individuals born after 1970. By contrast, the percentage of HCV genotype 2b increased in subsequent birth cohorts after 1920-1929. Significant changes in HCV genotype distribution were observed across Japan regardless of area.

Entities:  

Mesh：

Year:  2014        PMID： 24598252      PMCID： PMC9151254          DOI： 10.1017/S0950268814000478

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN： 0950-2688            Impact factor:   4.434


  12 in total

1.  Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: association of genotype with clinical parameters and with sex- and drug-related risk behaviours.

Authors:  C Matheï; E Wollants; J Verbeeck; M Van Ranst; G Robaeys; P Van Damme; F Buntinx
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

2.  Changing HCV genotypes distribution in Poland--relation to source and time of infection.

Authors:  Slawomir Chlabicz; Robert Flisiak; Oksana Kowalczuk; Anna Grzeszczuk; Barbara Pytel-Krolczuk; Danuta Prokopowicz; Lech Chyczewski
Journal:  J Clin Virol       Date:  2008-03-19       Impact factor: 3.168

3.  Molecular epidemiology of hepatitis C infection in U.S. veteran liver transplant recipients: evidence for decreasing relative prevalence of genotype 1B.

Authors:  H R Rosen; S Chou; A W Sasaki; D R Gretch
Journal:  Am J Gastroenterol       Date:  1999-10       Impact factor: 10.864

4.  Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users.

Authors:  M Bourlière; J M Barberin; M Rotily; V Guagliardo; I Portal; L Lecomte; S Benali; C Boustière; H Perrier; M Jullien; G Lambot; R Loyer; O LeBars; R Daniel; H Khiri; P Halfon
Journal:  J Viral Hepat       Date:  2002-01       Impact factor: 3.728

5.  Epidemiology of hepatitis C virus in japan.

Authors:  T Moriya; T Koyama; J Tanaka; S Mishiro; H Yoshizawa
Journal:  Intervirology       Date:  1999       Impact factor: 1.763

Review 6.  Changing trends in hepatitis C infection over the past 50 years in Japan.

Authors:  Hobyung Chung; Taisuke Ueda; Masatoshi Kudo
Journal:  Intervirology       Date:  2010-01-05       Impact factor: 1.763

7.  Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey.

Authors:  F McOmish; P L Yap; B C Dow; E A Follett; C Seed; A J Keller; T J Cobain; T Krusius; E Kolho; R Naukkarinen
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

8.  Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006.

Authors:  Francois Roman; Karin Hawotte; Daniel Struck; Anne-Marie Ternes; Jean-Yves Servais; Vic Arendt; Patrick Hoffman; Robert Hemmer; Therese Staub; Carole Seguin-Devaux; Jean-Claude Schmit
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

9.  The comparison of chronic hepatitis C treatment outcome between intravenous drug users and non-intravenous drug users.

Authors:  K Bojovic; J Simonovic; N Katanic; I Milosevic; I Pesic; D Delic; N Svirtlih; D J Jevtovic
Journal:  Biomed Pharmacother       Date:  2013-03-30       Impact factor: 6.529

10.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425
View more
  18 in total

1.  Current characteristics of hemophilia patients co-infected with HIV/HCV in Japan.

Authors:  Satoshi Miuma; Masaaki Hidaka; Mitsuhisa Takatsuki; Koji Natsuda; Akihiko Soyama; Hisamitsu Miyaaki; Yasuko Kanda; Yoko Tamada; Hidetaka Shibata; Eisuke Ozawa; Naota Taura; Susumu Eguchi; Kazuhiko Nakao
Journal:  Exp Ther Med       Date:  2017-12-07       Impact factor: 2.447

2.  The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma.

Authors:  Kazuyuki Mizuno; Hidenori Toyoda; Satoshi Yasuda; Toshifumi Tada; Takashi Kumada; Yasuhiro Sone; Junko Tanaka
Journal:  J Gastroenterol       Date:  2019-06-03       Impact factor: 7.527

3.  In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A.

Authors:  Preethi Krishnan; Jill Beyer; Neeta Mistry; Gennadiy Koev; Thomas Reisch; David DeGoey; Warren Kati; Andrew Campbell; Laura Williams; Wangang Xie; Carolyn Setze; Akhteruzzaman Molla; Christine Collins; Tami Pilot-Matias
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

4.  Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection.

Authors:  Sathej M Gopalakrishnan; Akshanth R Polepally; Sven Mensing; Amit Khatri; Rajeev M Menon
Journal:  Clin Pharmacokinet       Date:  2017-01       Impact factor: 6.447

5.  In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor.

Authors:  Warren Kati; Gennadiy Koev; Michelle Irvin; Jill Beyer; Yaya Liu; Preethi Krishnan; Thomas Reisch; Rubina Mondal; Rolf Wagner; Akhteruzzaman Molla; Clarence Maring; Christine Collins
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

6.  The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2.

Authors:  Sung Yong Han; Hyun Young Woo; Jeong Heo; Sang Gyu Park; Sung Ik Pyeon; Young Joo Park; Dong Uk Kim; Gwang Ha Kim; Hyung Hoi Kim; Geun Am Song; Mong Cho
Journal:  Korean J Intern Med       Date:  2019-03-19       Impact factor: 2.884

Review 7.  Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries.

Authors:  Masao Omata; Tatsuo Kanda; Osamu Yokosuka; Darrell Crawford; Mamun Al-Mahtab; Lai Wei; Alaaeldin Ibrahim; George K K Lau; Barjesh C Sharma; Saeed S Hamid; Wan-Long Chuang; A Kadir Dokmeci
Journal:  Hepatol Int       Date:  2015-05-05       Impact factor: 9.029

8.  Geographic distribution of HCV genotypes in Libya and analysis of risk factors involved in their transmission.

Authors:  Mohamed A Daw; Abdallah El-Bouzedi; Aghnaya A Dau
Journal:  BMC Res Notes       Date:  2015-08-21

9.  Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/Ribavirin Therapy in Chronic Hepatitis C.

Authors:  Po-sung Chu; Hirotoshi Ebinuma; Nobuhiro Nakamoto; Kazuo Sugiyama; Shingo Usui; Yuko Wakayama; Nobuhito Taniki; Akihiro Yamaguchi; Shunsuke Shiba; Yoshiyuki Yamagishi; Takaji Wakita; Toshifumi Hibi; Hidetsugu Saito; Takanori Kanai
Journal:  PLoS One       Date:  2015-05-12       Impact factor: 3.240

Review 10.  Simeprevir for the treatment of hepatitis C virus infection.

Authors:  Laure Izquierdo; François Helle; Catherine François; Sandrine Castelain; Gilles Duverlie; Etienne Brochot
Journal:  Pharmgenomics Pers Med       Date:  2014-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.